AMEX: NROr prezzo delle azioni, notizie, grafici, ricerca sulle azioni, profilo.

 (AMEX:NROr) Azioni Citazioni e riassunti delle notizie

Scotiabank analyst Meny Grauman maintains Bank of Montreal (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BMO#TSX">BMO</a>) with a Sector Outperform and lowers the price target from C$160 to C$159.

News

Price Target

Analyst Ratings

TSX:BMO

Scotiabank Maintains Sector Outperform on Bank of Montreal, Lowers Price Target to C$159

Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Sector Perform and raises the price target from $78 to $80.

BMRN

Scotiabank Maintains Sector Perform on Biomarin Pharmaceutical, Raises Price Target to $80

RBC Capital Markets analyst Logan Reich reiterated the Outperform rating on Domino&#8217;s Pizza Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>), <a target="_blank" href="https://www.benzinga.com/quote/DPZ/analyst-ratings" rel="noreferrer noopener">with a price forecast of $500.</a>
Domino&#8217;s will report its fourth-quarter results on 24th February, before the market opens.
The analyst remains curious about U.S. demand trends and market share, given competitors&#8217; results, potential partnership with DoorDash, Inc, and improvements in the international business.
The analyst notes that while Uber Technologies, Inc&#8217;s exclusivity agreement ends at the end of the first quarter, a potential renewal or new partnership with DoorDash could be announced.
Per the analyst, extending Uber&#8217;s exclusivity would be negative, as investors may interpret it as a sign of weaker demand, given that DoorDash&#8217;s market share in the U.S. is roughly three times that of Uber&#8217;s.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/02/43818486/yum-brands-moves-kfcs-us-headquarters-to-texas-in-strategic-shift" rel="noreferrer noopener">Yum! Brands Moves KFC&#8217;s US Headquarters To Texas In Strategic Shift</a>
This apart, Reich notes that with Yum! Brands, Inc. already reporting and Papa John&#8217;s International, Inc. having preannounced, the interest in U.S. category growth is somewhat reduced heading into Domino&#8217;s earnings.
The analyst writes that Domino&#8217;s will continue to gain market share due to its strong value positioning and marketing advantage over &#8220;independent&#8221; pizza businesses.
However, for the fourth quarter, the U.S. same-store sales estimate is lowered to 1.0% due to softer category growth, compared to the consensus of 1.3%.
Price Action: DPZ shares are trading lower by 1.14% to $469.93 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43813431/e-commerce-company-etsy-q4-earnings-sales-miss-pressured-consumer-spending-active-buyers-dip-and-more" target="_blank" rel="noreferrer noopener">E-Commerce Company Etsy Q4 Earnings: Sales Miss, Pressured Consumer Spending, Active Buyers Dip And More</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

Reiteration

Markets

Trading Ideas

General

What To Expect From Domino's Pizza Q4 Earnings?

Citigroup analyst Peter Christiansen maintains CoStar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) with a Buy and lowers the price target from $88 to $86.

CSGP

Citigroup Maintains Buy on CoStar Gr, Lowers Price Target to $86

On Wednesday, <a target="_blank" href="https://www.benzinga.com/topic/chip-stocks" rel="noreferrer noopener">U.S. chip equipment maker</a> Lam Research Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) launched two new tools for building advanced artificial intelligence chips. The company introduced Akara, an innovative plasma etch and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43812049/lam-research-unveils-industrys-most-advanced-conductor-etch-technology-to-date" rel="noreferrer noopener">advanced conductor etch tool</a>.
Akara delivers novel plasma processing technologies that enable the etch precision and performance needed for 3D chipmaking.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43847808/lenovo-q3-earnings-20-revenue-jump-ai-pcs-and-smartphones-power-market-expansion" rel="noreferrer noopener">Lenovo Q3 Earnings: 20% Revenue Jump, AI PCs and Smartphones Power Market Expansion</a>
Akara enables the scaling of gate-all-around (GAA) transistors, 6F2&nbsp;DRAM, and 3D NAND devices and is extendible to 4F2&nbsp;DRAM, complementary field-effect transistors, and 3D DRAM.
These devices require etch steps and Extreme Ultraviolet (EUV) lithography patterning to form complex 3D structures.&nbsp;
Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) co-COO Dr. Y.J. Mii noted critical plasma etch capabilities will be integral to solving the many semiconductor production challenges the new, more powerful device architectures pose.
Lam Research also showcased ALTUS&nbsp;Halo, an <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43812136/lam-research-ushers-in-new-era-of-semiconductor-metallization-with-altus-halo-for-molybdenum-atomi" rel="noreferrer noopener">atomic layer deposition</a> (ALD) tool that harnesses the metal molybdenum&#8217;s capabilities in producing leading-edge semiconductors.
ALTUS Halo delivers exceptional feature fill and high-precision deposition of low-resistivity, void-free molybdenum metallization for advanced semiconductor devices. ALTUS Halo could pave the way for scaling advanced memory and logic chips for future AI, cloud computing, and next-generation smart devices.
Early adoption has begun at leading high-volume 3D NAND manufacturers with fabs in Korea and&nbsp;Singapore&nbsp;and advanced logic fabs, while development continues with DRAM customers.
Lam Research&#8217;s ALTUS Halo tool has enabled Micron Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) to bring molybdenum into mass production.
During the <a target="_blank" href="https://investor.lamresearch.com/events?item=82" rel="noreferrer noopener">2025 investor day</a>, CFO Douglas Bettinger said Lam expects revenue of between $25 billion-$28 billion in 2028 and adjusted EPS of $6-$7. Bettinger noted that adjusted gross margins will reach about 50% by 2028.
Lam Research plans to return over 85% of free cash flow in the near term. It expects Customer Support Business Group (CSBG) growth to be flat in 2025.
The company expects wafer fabrication equipment growth to be mid-high for the next several years. It also noted that customers are cost-conscious and sensitive to the return on investment and the speed with which they can ramp new fabs.
Recently, Lam Research committed $1.2 billion to boost India&#8217;s semiconductor ecosystem, which could be worth <a target="_blank" href="https://www.benzinga.com/government/regulations/25/02/43664402/lam-research-commits-1-2-billion-investment-in-india-eyes-63-billion-semiconductor-growth-market" rel="noreferrer noopener">$63 billion by 2026</a>.
Cantor Fitzgerald analyst Matthew Prisco reiterated Lam Research with an Overweight and a <a target="_blank" href="https://www.benzinga.com/quote/LRCX/analyst-ratings" rel="noreferrer noopener">$100&nbsp;price target</a>.
Price Action: LRCX stock is up 1.24% at $88.75 at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43813469/analog-devices-beats-q1-estimates-raises-dividend-as-automotive-revenue-declines" target="_blank" rel="noreferrer noopener">Analog Devices Beats Q1 Estimates, Raises Dividend As Automotive Revenue Declines</a></li>
</ul>

Tech

LRCX

Lam Research Unveils AI Chipmaking Tools, Projects Big Returns

Citigroup analyst Scott Gruber maintains RPC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RES#NYSE">RES</a>) with a Sell and raises the price target from $5.25 to $5.5.

Citigroup Maintains Sell on RPC, Raises Price Target to $5.5

<a href="https://asia.nikkei.com/Business/Energy/GE-unit-to-join-foreign-bid-for-huge-Japan-power-grid" title="https://asia.nikkei.com/Business/Energy/GE-unit-to-join-foreign-bid-for-huge-Japan-power-grid">https://asia.nikkei.com/Business/Energy/GE-unit-to-join-foreign-bid-for-huge-Japan-power-grid</a>

'GE unit to join foreign bid for huge Japan power grid' -Nikkei

Citigroup analyst Scott Gruber maintains Core Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) with a Sell and raises the price target from $14 to $15.

Citigroup Maintains Sell on Core Laboratories, Raises Price Target to $15

WIIM

DLTR

Dollar Tree shares are trading higher following a report suggesting that Apollo Global, Sycamore and Brigade Capital are competing to acquire Family Dollar.

Citigroup analyst Nicholas Jones maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Neutral and lowers the price target from $56 to $53.

ETSY

Citigroup Maintains Neutral on Etsy, Lowers Price Target to $53

Apollo Global, Sycamore And Brigade Capital Are Competing To Acquire Family Dollar

Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Neutral and raises the price target from $206 to $215.

KRYS

Citigroup Maintains Neutral on Krystal Biotech, Raises Price Target to $215

Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Neutral and raises the price target from $81 to $82.

Citigroup Maintains Neutral on Biomarin Pharmaceutical, Raises Price Target to $82

ARES

DOMH

EMCG

FCNCA

HOOD

IBKR

RILY

ROOT

SOFI

STEP

Shares of companies within the broader financial sector are trading lower amid overall market weakness. Investors may be evaluating the risk of inflation as the retail sector shows early signs of a weaker consumer.

Citigroup analyst Ronald Josey maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and raises the price target from $275 to $280.

Citigroup Maintains Buy on Wix.com, Raises Price Target to $280

Citigroup analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and lowers the price target from $67 to $64.

IONS

Citigroup Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $64

E-commerce company&nbsp;Etsy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43813431/e-commerce-company-etsy-q4-earnings-sales-miss-pressured-consumer-spending-active-buyers-dip-and-more" rel="noreferrer noopener">fourth-quarter FY24 earnings yesterday</a>. The following are the opinions of different analysts on the same.
Needham analyst Bernie McTernan reiterated a B<a href="https://www.benzinga.com/quote/ETSY/analyst-ratings">uy rating on the shares and maintained a price forecast of $60.00</a>. In the fourth quarter, GMS fell short of expectations, primarily due to ongoing challenges in consumer discretionary spending, noted the analyst.
Additionally, the company chose to focus on long-term initiatives instead of short-term growth, along with a shorter holiday season. The shift to long-term investments is estimated to have impacted GMS by a few hundred million, but it also laid the groundwork for initiatives expected to drive growth in 2025, such as personalization, a new marketing mix, and app development.
The analyst is taking a more conservative approach to the GMS model, assuming only a slight improvement in the YoY declines in the second quarter, 4% YoY declines in the latter half of 2025 and &lt;1% GMS growth in &#8217;26E, considering this as a prudent approach given the uncertainty from leadership changes, strategic shifts, and ongoing macroeconomic pressures on consumer spending.
ETSY is boosting customer engagement and frequency through initiatives like gifting, quality improvements, a new loyalty program, and app investments.
Gifting sales in 2024 outperformed the broader marketplace, contributing 29% to total GMS. Although its still early, management is seeing promising signs of increased frequency and user engagement on Etsy Insider, noted the analyst.
For FY25E, the analyst lowers GMS estimates by -6% and FY25E adj. EBITDA estimates come down by ~10%. The challenges impacting e-commerce consumer spending have affected the entire sector, but the analyst notes Etsy has the opportunity to emerge stronger.
By leveraging the larger scale gained during the pandemic, Etsy can enhance the user experience, which should drive increased consideration for the marketplace and more frequent purchases, concluded the analyst.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43846469/walmart-q4-earnings-shine-but-soft-fy26-outlook-disappoints-street" rel="noreferrer noopener">Walmart Q4 Earnings Shine, But Soft FY26 Outlook Disappoints Street</a>
Canaccord Genuity analyst Maria Ripps maintains a Buy rating on the shares and lowers the price forecast from $105.00 to $76.00.
The analyst said that Etsy posted mixed results for the quarter, with active buyers, GMS, and revenue falling short of expectations, while take rate and profitability exceeded forecasts.
Marketplace activity was sluggish in October and November, and the company acknowledged that prioritizing foundational product development over short-term GMS drivers led to a GMS headwind of several hundred million, impacting the fourth quarter and first quarter.
However, Etsy returned to a more balanced product development strategy at the start of the year, expecting benefits to grow throughout 2025.
With strategic initiatives like expanding Gifting, boosting loyalty program adoption, improving personalization, and increasing app downloads, management anticipates improving GMS year-over-year trends.
Nevertheless, the first quarter is expected to be another tough quarter, with GMS declining similarly to the fourth quarter. Profitability expectations were slightly below forecasts, with margins expected to improve in the second half of 2025.
Despite pressure on Etsy shares, the stock now trades at about 3x FY25 revenue and 10x adjusted EBITDA, suggesting significant negative sentiment is already priced in.
If consumer discretionary spending rebounds and growth initiatives yield stronger results, investor confidence could recover, with further upside if the de minimis exemption is repealed and competition eases, noted the analyst.
Price Action: ETSY shares are trading lower by 1.47% at $50.77 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/25/02/43778605/tesla-files-fresh-lawsuit-against-matthews-after-court-defeat" target="_blank" rel="noreferrer noopener">Tesla Files Fresh Lawsuit Against Matthews After Court Defeat</a></li>
</ul>
Image via Shutterstock.

Etsy Stock Declines Amid Q4 Shortfall But Long-Term Strategy Could Pay Off, Say Analysts

Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRSP, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for CRISPR Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 53%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $148,003, and 12 are calls, for a total amount of $571,849.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $75.0 for CRISPR Therapeutics over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for CRISPR Therapeutics's big money trades within a strike price range of $40.0 to $75.0 over the last 30 days.
<h3>CRISPR Therapeutics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740076245_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRSP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.95</td>
<td>$1.9</td>
<td>$1.9</td>
<td>$60.00</td>
<td>$76.0K</td>
<td>1.3K</td>
<td align="right">417</td>
</tr>
<tr>
<td>CRSP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.7</td>
<td>$12.5</td>
<td>$12.5</td>
<td>$50.00</td>
<td>$62.5K</td>
<td>1.0K</td>
<td align="right">0</td>
</tr>
<tr>
<td>CRSP</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$13.4</td>
<td>$11.1</td>
<td>$12.2</td>
<td>$47.50</td>
<td>$61.0K</td>
<td>59</td>
<td align="right">0</td>
</tr>
<tr>
<td>CRSP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$11.9</td>
<td>$11.7</td>
<td>$11.7</td>
<td>$40.00</td>
<td>$58.5K</td>
<td>571</td>
<td align="right">107</td>
</tr>
<tr>
<td>CRSP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$10.1</td>
<td>$9.5</td>
<td>$10.1</td>
<td>$40.00</td>
<td>$57.5K</td>
<td>180</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About CRISPR Therapeutics</h3>
Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Following our analysis of the options activities associated with CRISPR Therapeutics, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of CRISPR Therapeutics</h3>
<ul>
<li>With a volume of 1,764,822, the price of CRSP is down -4.38% at $50.7. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 76 days.</li>
</ul>
<h3>What The Experts Say On CRISPR Therapeutics</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $73.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Underweight rating on CRISPR Therapeutics with a target price of $32. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on CRISPR Therapeutics, which currently sits at a price target of $120. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on CRISPR Therapeutics with a target price of $48. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $84. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on CRISPR Therapeutics, which currently sits at a price target of $82. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CRISPR Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

CRSP

Market Whales and Their Recent Bets on CRSP Options

Whales with a lot of money to spend have taken a noticeably bullish stance on Wingstop.
Looking at options history for Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 11% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $164,302 and 5, calls, for a total amount of $399,890.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $400.0 for Wingstop, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Wingstop's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Wingstop's substantial trades, within a strike price spectrum from $240.0 to $400.0 over the preceding 30 days.
<h3>Wingstop 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740076240_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WING</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$62.0</td>
<td>$58.5</td>
<td>$60.85</td>
<td>$250.00</td>
<td>$152.1K</td>
<td align="right">7</td>
<td align="right">26</td>
</tr>
<tr>
<td>WING</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$27.4</td>
<td>$25.8</td>
<td>$26.5</td>
<td>$240.00</td>
<td>$145.7K</td>
<td align="right">17</td>
<td align="right">6</td>
</tr>
<tr>
<td>WING</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$27.9</td>
<td>$25.4</td>
<td>$25.4</td>
<td>$270.00</td>
<td>$63.5K</td>
<td align="right">209</td>
<td align="right">11</td>
</tr>
<tr>
<td>WING</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$19.8</td>
<td>$18.3</td>
<td>$19.5</td>
<td>$310.00</td>
<td>$48.7K</td>
<td align="right">116</td>
<td align="right">0</td>
</tr>
<tr>
<td>WING</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$11.2</td>
<td>$10.3</td>
<td>$10.5</td>
<td>$250.00</td>
<td>$40.9K</td>
<td align="right">328</td>
<td align="right">188</td>
</tr>
</tbody>
</table>

<h3>About Wingstop</h3>
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, reaching north of 2,200 global stores at the end of 2023, rendering Wingstop the 31st-largest restaurant brand in the US by system sales, according to Euromonitor data. With a 98% franchised model, Wingstop generates the lion share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
<h3>Where Is Wingstop Standing Right Now?</h3>
<ul>
<li>With a volume of 1,021,351, the price of WING is down -6.76% at $247.1. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 69 days.</li>
</ul>
<h3>Expert Opinions on Wingstop</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $369.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Stephens &amp; Co. keeps a Overweight rating on Wingstop with a target price of $400. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Wingstop, targeting a price of $315. 
&#x2A; An analyst from TD Securities has decided to maintain their Buy rating on Wingstop, which currently sits at a price target of $305. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Wingstop, which currently sits at a price target of $375. 
&#x2A; Reflecting concerns, an analyst from Stephens &amp; Co. lowers its rating to Overweight with a new price target of $450.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Wingstop with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

WING

Wingstop's Options: A Look at What the Big Money is Thinking

Citigroup analyst Jason Bazinet maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Neutral and raises the price target from $70 to $103.

ROKU

Citigroup Maintains Neutral on Roku, Raises Price Target to $103

Learn About Cryptocurrency

acf/sidebar-related-posts

Learn about this leading blockchain platform that supports decentralized applications and smart contracts.

What is Ethereum?

Earning interest on your Ethereum is a great way to grow your cryptocurrency holdings. Find out how to earn interest on your Ethereum in 4 easy steps.

How to Earn Interest on Ethereum

Discover the 10 best cryptocurrencies to invest in for January 2025. Stay ahead in the crypto market with our expert insights and analysis! Learn more now!

10 Best Cryptocurrencies to Invest In for February 2025

10 Best Cryptocurrencies to Invest in for January 2025

Discover the best altcoins to invest in for high potential returns. Our top altcoin picks include Ethereum, Solana, Ripple, Dogecoin, Toncoin.

Top 10 Best Altcoins • Benzinga Crypto

10 Best Altcoins in November 2024

Top Cryptocurrency News

acf/news-feed

Aperto	-
Chiuso	-
Volume / Media	0 / 924.32K
Intervallo giornaliero	- - -
Intervallo a 52 settimane	0.00 - 0.20
Capitalizzazione di mercato	-
Rapporto P/E	-
Rendimento del dividendo	-
Exchange	AMEX
RSI	0
Vendite allo scoperto	-
Periodo di copertura	-

Aperto	-
Chiuso	-
Volume / Media	0 / 924.32K
Intervallo giornaliero	- - -
Intervallo a 52 settimane	0.00 - 0.20
Capitalizzazione di mercato	-
Rapporto P/E	-
Rendimento del dividendo	-
Exchange	AMEX
RSI	0
Vendite allo scoperto	-
Periodo di copertura	-

Comments

(NROr) Previsione

(AMEX:NROr) Azioni Citazioni e riassunti delle notizie

Notizie recenti

Dati finanziari

Confronta

FAQ

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Nome

Ricavi Variazioni
Lordo Variazioni
EBITDA Variazioni
EBIT Variazioni
Utili Variazioni